FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models

C. Corno, S. Stucchi, M. De Cesare, N. Carenini, S. Stamatakos, E. Ciusani, L. Minoli, E. Scanziani, C. Argueta, Y. Landesman, N. Zaffaroni, L. Gatti, P. Perego

Research output: Contribution to journalArticlepeer-review

Cite this